All In Biotech

NDA 018074 · Acertis Pharms

Phendimetrazine Tartrate

Phendimetrazine Tartrate · Oral

Last checked: Nov 20, 2026Latest source record: Nov 13, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Apr 16, 1979

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

0 Phase 3, 0 recruiting

FAERS reports

58

23 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 19, 2025.

INDICATIONS AND USAGE Phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of greater than or equal to 30 kg/m 2 or greater than or equal to 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters The usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below. Phendimetrazine tartrate is indicated for use as monotherapy only. Body Mass Index Table

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 16, 1979 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • PHENDIMETRAZINE TARTRATE · PHENDIMETRAZINE TARTRATE 105MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Phendimetrazine" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9
  • pain7
  • headache6
  • weight increased6
  • back pain5
  • wrong technique in product usage process5
  • choroidal effusion4
  • dyspnoea4
  • fatigue4
  • myopia4
  • ocular hypertension4
  • off label use4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20083
20101
20114
20121
20141
20155
20166
20172
20182
20197
20204
20212
20222
20235
20248
20253
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: Acertis Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.